CVE-2017-17678 : Security Advisory and Response

BMC Remedy Mid Tier 9.1SP3 software is vulnerable to cross-site scripting (XSS) attacks due to a security flaw in a legacy utility.

Understanding CVE-2017-17678

This CVE identifies a cross-site scripting vulnerability in BMC Remedy Mid Tier 9.1SP3.

What is CVE-2017-17678?

CVE-2017-17678 is a security vulnerability in BMC Remedy Mid Tier 9.1SP3 that allows for DOM-based cross-site scripting attacks.

The Impact of CVE-2017-17678

The vulnerability can be exploited by attackers to execute malicious scripts in the context of a user's browser, potentially leading to unauthorized access or data theft.

Technical Details of CVE-2017-17678

BMC Remedy Mid Tier 9.1SP3 is affected by the following:

Vulnerability Description

A security flaw in a legacy utility enables DOM-based cross-site scripting attacks, posing a risk to the integrity of user data.

Affected Systems and Versions

Product: BMC Remedy Mid Tier 9.1SP3
Vendor: BMC
Version: Not applicable

Exploitation Mechanism

The vulnerability allows attackers to inject and execute malicious scripts within the user's browser, potentially compromising sensitive information.

Mitigation and Prevention

Taking immediate steps and implementing long-term security practices are crucial to mitigating the risks associated with CVE-2017-17678.

Immediate Steps to Take

Disable the legacy utility or apply security patches provided by BMC.
Educate users about the risks of XSS attacks and encourage safe browsing habits.

Long-Term Security Practices

Regularly update and patch BMC Remedy Mid Tier to address security vulnerabilities.
Conduct security assessments and penetration testing to identify and remediate potential weaknesses.

Patching and Updates

Stay informed about security advisories from BMC and promptly apply recommended patches to secure the system.